BEAR® is a fundamental paradigm shift in our approach to treating ACL injuries: rather than removing a torn ACL and replacing it with a tendon graft, BEAR® uses an implant containing the patient's own blood to stimulate healing of the native ACL. This less invasive procedure lends itself to faster recovery of muscle strength after surgery and prevents morbidity associated with traditional grafts, such as kneeling pain or hamstring deficits.
The BEAR-MOON trial addresses the question of whether this new and less invasive surgical procedure can provide non-inferior outcomes to the gold standard of treatment in terms of knee laxity and patient-reported outcomes. The trial is being conducted by academy-trained orthopaedic surgeons at academic medical institutions across the United States.
Individuals who have recently suffered an ACL injury and are between the ages of 18 and 55 may be candidates to participate in the BEAR-MOON trial. Resources for prospective and current participants are available to answer any questions about the study.